{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["55"],"submitter":["Paccoud O"],"pubmed_abstract":["<h4>Background</h4>Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France.<h4>Methods</h4>We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables.<h4>Findings</h4>We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, in"],"journal":["The Lancet regional health. Europe"],"pagination":["101365"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12426822"],"repository":["biostudies-literature"],"pubmed_title":["Yeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study."],"pmcid":["PMC12426822"],"pubmed_authors":["Imbert S","Favennec L","Pihet M","Chesnay A","Bonhomme J","Gangneux JP","Cassaing S","Boukris-Sitbon K","Poirier P","Desbois-Nogard N","Chouaki T","Huguenin A","Lortholary O","Bougnoux ME","Paccoud O","Dalle F","Morio F","French Mycoses Study Group","Nicolas M","Demar M","Mariani P","Durieux MF","Mahinc C","Lanternier F","Paugam A","Bellanger AP","Chachaty E","Alanio A","Letscher-Bru V","Perraud-Cateau E","Obadia T","Desnos-Ollivier M","Desoubeaux G","Micaelo M","Sasso M","Merabet L","Hasseine L"],"additional_accession":[]},"is_claimable":false,"name":"Yeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.","description":"<h4>Background</h4>Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France.<h4>Methods</h4>We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables.<h4>Findings</h4>We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, in","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-01T15:56:55.279Z","creation":"2026-04-08T13:55:53.153Z"},"accession":"S-EPMC12426822","cross_references":{"pubmed":["40950950"],"doi":["10.1016/j.lanepe.2025.101365"]}}